rifaximin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, rifamycin derivatives 2379 80621-81-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rifaximine
  • rifaximin
  • xifaxan
  • refaximin
Rifaximin is a semi-synthetic derivative of rifampin and acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase blocking one of the steps in transcription. This results in inhibition of bacterial protein synthesis and consequently inhibits the growth of bacteria.
  • Molecular weight: 785.89
  • Formula: C43H51N3O11
  • CLOGP: 7.19
  • LIPINSKI: 3
  • HAC: 14
  • HDO: 5
  • TPSA: 198.38
  • ALOGS: -5.03
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.04 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 10.91 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0.40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.068 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 5.984 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 23.281 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 7.362 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 3.900 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 11.910 % High 1
herg hERG pIC50 4.582 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 4.613 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 10.965 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 4.610 % High 1
kinase-safety-class ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,KDR,KIT,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 53
kinase-selectivity-class AXL,GRK2,MAP2K6,PDK1,ZAP70 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 5 Moderate 0.72
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 9.333 High 1
mh-clint Mouse hepatocyte intrinsic clearance 11.482 High 1
mppb Mouse plasma protein binding (% unbound) 3.290 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 45.604 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 5.910 % High 1
rat-kpuu-brain Rat brain Kpuu 0.010 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 6.339 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 26.950 % High 1
rppb Rat plasma protein binding (% unbound) 4.390 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 386.367 uM High 1

Approvals:

DateAgencyCompanyOrphan
May 25, 2004 FDA SALIX PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 708.56 16.46 550 12103 456001 90159793
Inability to afford medication 472.27 16.46 108 12545 3514 90612280
Hepatic encephalopathy 420.36 16.46 130 12523 13642 90602152
Ammonia increased 281.59 16.46 76 12577 4910 90610884
Hospitalisation 268.58 16.46 186 12467 127914 90487880
Insurance issue 250.27 16.46 83 12570 10875 90604919
Therapy interrupted 181.37 16.46 103 12550 50005 90565789
Ascites 161.73 16.46 94 12559 47646 90568148
Chronic hepatic failure 126.53 16.46 27 12626 632 90615162
Hepatic failure 126.06 16.46 75 12578 39653 90576141
Gastrointestinal bacterial overgrowth 121.28 16.46 27 12626 774 90615020
Varices oesophageal 120.84 16.46 37 12616 3742 90612052
Hepatic cirrhosis 112.02 16.46 83 12570 63170 90552624
Small intestinal obstruction 80.43 16.46 45 12608 21189 90594605
Portal hypertension 74.04 16.46 27 12626 4674 90611120
Incontinence 72.29 16.46 36 12617 13399 90602395
Quality of life decreased 70.37 16.46 34 12619 11855 90603939
Nerve injury 69.50 16.46 33 12620 11073 90604721
Drug specific antibody 53.25 16.46 18 12635 2494 90613300
Abdominal distension 50.85 16.46 76 12577 130525 90485269
Liver transplant 50.69 16.46 17 12636 2300 90613494
Cirrhosis alcoholic 50.07 16.46 11 12642 296 90615498
Blood bilirubin increased 49.29 16.46 44 12609 43426 90572368
Hepatic infarction 46.07 16.46 12 12641 674 90615120
Hospice care 40.69 16.46 22 12631 9682 90606112
Abdominal pain 39.33 16.46 133 12520 395588 90220206
Arthropathy 37.03 16.46 4 12649 366238 90249556
Mental status changes 36.94 16.46 38 12615 44641 90571153
Confusional state 36.80 16.46 128 12525 386077 90229717
Portal hypertensive gastropathy 36.68 16.46 11 12642 1036 90614758
Frequent bowel movements 35.91 16.46 42 12611 56893 90558901
Therapy cessation 35.77 16.46 34 12619 36327 90579467
Encephalopathy 35.72 16.46 38 12615 46406 90569388
Diarrhoea 35.46 16.46 238 12415 938952 89676842
Glossodynia 33.88 16.46 3 12650 321776 90294018
Maternal exposure during pregnancy 33.81 16.46 5 12648 360058 90255736
Pneumatosis intestinalis 33.71 16.46 14 12639 3423 90612371
Contraindicated product administered 33.66 16.46 3 12650 320136 90295658
Acute hepatic failure 32.05 16.46 26 12627 22535 90593259
Alopecia 29.82 16.46 16 12637 495055 90120739
Pancreatitis 29.13 16.46 42 12611 69784 90546010
Wound 28.92 16.46 4 12649 302976 90312818
Paracentesis 28.68 16.46 9 12644 986 90614808
Epstein-Barr virus infection reactivation 28.02 16.46 10 12643 1627 90614167
Rheumatoid arthritis 27.94 16.46 8 12645 362606 90253188
Anaemia 27.78 16.46 110 12543 352692 90263102
Treatment noncompliance 25.93 16.46 34 12619 51693 90564101
Musculoskeletal stiffness 25.88 16.46 5 12648 296527 90319267
Liver disorder 25.62 16.46 54 12599 121215 90494579
Impaired quality of life 25.39 16.46 23 12630 23121 90592673
Ammonia abnormal 24.55 16.46 6 12647 260 90615534
Haemorrhagic diathesis 24.50 16.46 13 12640 5511 90610283
Hepatocellular carcinoma 24.19 16.46 10 12643 2418 90613376
Joint swelling 24 16.46 21 12632 503279 90112515
Drug hypersensitivity 23.78 16.46 18 12635 463591 90152203
Amoebic colitis 23.63 16.46 3 12650 0 90615794
Exposure during pregnancy 23.10 16.46 3 12650 238407 90377387
Pseudomembranous colitis 22.70 16.46 11 12642 3857 90611937
Lower respiratory tract infection 22.36 16.46 4 12649 250655 90365139
Hepatorenal syndrome 22.33 16.46 9 12644 2039 90613755
Complications of transplanted liver 21.96 16.46 6 12647 405 90615389
Vascular device infection 21.85 16.46 16 12637 11936 90603858
Psoriatic arthropathy 21.82 16.46 3 12650 228332 90387462
Hypoproteinaemia 21.71 16.46 10 12643 3132 90612662
Abdominal discomfort 21.47 16.46 21 12632 477307 90138487
Multiple organ dysfunction syndrome 21.38 16.46 36 12617 68300 90547494
Hyponatraemia 21.06 16.46 53 12600 133485 90482309
Drug intolerance 20.94 16.46 19 12634 447572 90168222
Hepatic hydrothorax 20.82 16.46 4 12649 54 90615740
Sinusitis 20.77 16.46 11 12642 343077 90272717
Swelling 20.56 16.46 17 12636 419041 90196753
Gastric varices 20.32 16.46 5 12648 223 90615571
Tendon pain 20.03 16.46 10 12643 3738 90612056
Atrioventricular block complete 19.92 16.46 14 12639 9797 90605997
Hypoalbuminaemia 19.84 16.46 17 12636 15880 90599914
Therapeutic product effect decreased 19.81 16.46 7 12646 277564 90338230
Hepatic enzyme increased 19.81 16.46 13 12640 360723 90255071
Haematemesis 19.81 16.46 24 12629 33702 90582092
Renal failure 19.63 16.46 51 12602 130956 90484838
Aplasia 19.44 16.46 10 12643 3981 90611813
Hypersensitivity 19.32 16.46 21 12632 454656 90161138
Platelet count abnormal 18.66 16.46 10 12643 4325 90611469
Portal vein thrombosis 18.64 16.46 9 12644 3129 90612665
Autoimmune pancytopenia 18.49 16.46 4 12649 100 90615694
Drug interaction 18.46 16.46 82 12571 276371 90339423
Acute generalised exanthematous pustulosis 17.81 16.46 15 12638 13688 90602106
Gastric antral vascular ectasia 17.81 16.46 6 12647 823 90614971
Tracheal obstruction 17.63 16.46 4 12649 125 90615669
Hepatic cancer 17.55 16.46 10 12643 4871 90610923
Flatulence 17.42 16.46 25 12628 41342 90574452
Clostridium difficile colitis 17.33 16.46 20 12633 26686 90589108
Septic shock 17.22 16.46 37 12616 84123 90531671
Herpes simplex viraemia 17.17 16.46 5 12648 425 90615369
Hypervolaemia 17.14 16.46 22 12631 32735 90583059
Nasopharyngitis 17.08 16.46 19 12634 407085 90208709
Mobility decreased 16.77 16.46 7 12646 250727 90365067
Portal shunt 16.73 16.46 3 12650 27 90615767
Overgrowth bacterial 16.56 16.46 4 12649 165 90615629
Splenomegaly 16.49 16.46 14 12639 12910 90602884

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic encephalopathy 601.69 17.00 208 11119 16234 42593774
Death 509.73 17.00 621 10706 470564 42139444
Inability to afford medication 491.93 17.00 114 11213 2016 42607992
Hospitalisation 336.66 17.00 222 11105 74108 42535900
Insurance issue 243.42 17.00 75 11252 4041 42605967
Ammonia increased 217.94 17.00 71 11256 4588 42605420
Hepatic cirrhosis 200.60 17.00 100 11227 19602 42590406
Therapy interrupted 186.27 17.00 99 11228 22151 42587857
Ascites 165.84 17.00 130 11197 56548 42553460
Hepatic failure 160.58 17.00 109 11218 37991 42572017
Encephalopathy 86.08 17.00 78 11249 41255 42568753
Hepatorenal syndrome 77.46 17.00 29 11298 2825 42607183
Portal hypertensive gastropathy 70.55 17.00 20 11307 803 42609205
Hepatocellular carcinoma 67.22 17.00 36 11291 8158 42601850
Chronic hepatic failure 65.60 17.00 18 11309 640 42609368
Liver transplant 61.06 17.00 24 11303 2667 42607341
Varices oesophageal 56.04 17.00 26 11301 4339 42605669
Hospice care 55.08 17.00 32 11295 8481 42601527
Oesophageal varices haemorrhage 51.07 17.00 23 11304 3584 42606424
Confusional state 46.76 17.00 123 11204 167474 42442534
Megacolon 43.63 17.00 18 11309 2267 42607741
Abdominal distension 41.54 17.00 71 11256 71664 42538344
Hyperammonaemic encephalopathy 40.37 17.00 18 11309 2740 42607268
Liver disorder 40.04 17.00 51 11276 39593 42570415
Hyperammonaemia 39.15 17.00 25 11302 7841 42602167
Hepatitis C 37.96 17.00 27 11300 10106 42599902
Asterixis 37.40 17.00 14 11313 1363 42608645
Portal hypertension 36.39 17.00 20 11307 4767 42605241
Sopor 33.69 17.00 28 11299 13174 42596834
Febrile neutropenia 32.99 17.00 5 11322 185698 42424310
Cirrhosis alcoholic 32.33 17.00 11 11316 811 42609197
Ureaplasma infection 30.98 17.00 10 11317 626 42609382
Poverty of speech 30.69 17.00 8 11319 233 42609775
Symptom recurrence 29.34 17.00 12 11315 1478 42608530
Portal vein thrombosis 29.16 17.00 17 11310 4532 42605476
Portal shunt procedure 28.54 17.00 5 11322 18 42609990
Peritonitis bacterial 27.23 17.00 19 11308 6896 42603112
Diarrhoea 27.15 17.00 212 11115 460637 42149371
Pseudomembranous colitis 26.35 17.00 14 11313 3119 42606889
Abdominal pain 26.15 17.00 110 11217 190361 42419647
Abdominal cavity drainage 25.63 17.00 8 11319 449 42609559
Paracentesis 25.17 17.00 8 11319 476 42609532
Jaundice 25.16 17.00 38 11289 34551 42575457
Hepatic cancer 23.77 17.00 19 11308 8461 42601547
Clostridium test positive 23.75 17.00 16 11311 5489 42604519
Functional gastrointestinal disorder 23.45 17.00 12 11315 2476 42607532
Microscopic enteritis 21.70 17.00 3 11324 0 42610008
Ammonia abnormal 21.26 17.00 5 11322 94 42609914
Disease complication 21.08 17.00 12 11315 3058 42606950
Mental status changes 20.91 17.00 39 11288 42076 42567932
Biopsy liver 20.42 17.00 6 11321 274 42609734
Rectal haemorrhage 19.89 17.00 42 11285 49564 42560444
Blood bilirubin increased 19.59 17.00 38 11289 42214 42567794
Skin necrosis 19.54 17.00 15 11312 6299 42603709
Hepatic lesion 19.24 17.00 13 11314 4481 42605527
Sprue-like enteropathy 19.12 17.00 7 11320 640 42609368
Treatment noncompliance 18.85 17.00 35 11292 37637 42572371
Condition aggravated 18.77 17.00 126 11201 260628 42349380
Toxicity to various agents 18.70 17.00 20 11307 229116 42380892
Therapy cessation 18.60 17.00 25 11302 20425 42589583
Enterococcus test positive 18.46 17.00 9 11318 1676 42608332
Hypervolaemia 17.66 17.00 26 11301 23099 42586909
Factor V inhibition 17.08 17.00 5 11322 225 42609783

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1040.08 15.02 942 20382 697927 109870048
Hepatic encephalopathy 897.98 15.02 297 21027 27959 110540016
Inability to afford medication 892.94 15.02 197 21127 3879 110564096
Insurance issue 483.88 15.02 147 21177 10465 110557510
Hospitalisation 456.01 15.02 304 21020 142189 110425786
Ammonia increased 405.05 15.02 121 21203 8129 110559846
Therapy interrupted 357.78 15.02 180 21144 49642 110518333
Ascites 301.43 15.02 200 21124 92608 110475367
Hepatic failure 215.56 15.02 145 21179 68594 110499381
Hepatic cirrhosis 212.90 15.02 143 21181 67483 110500492
Varices oesophageal 152.39 15.02 56 21268 7159 110560816
Chronic hepatic failure 133.98 15.02 34 21290 1237 110566738
Gastrointestinal bacterial overgrowth 123.04 15.02 28 21296 635 110567340
Portal hypertensive gastropathy 102.42 15.02 30 21294 1878 110566097
Encephalopathy 99.55 15.02 99 21225 80956 110487019
Hepatocellular carcinoma 99.25 15.02 45 21279 9835 110558140
Portal hypertension 98.50 15.02 43 21281 8594 110559381
Hepatorenal syndrome 98.26 15.02 36 21288 4561 110563414
Liver transplant 87.33 15.02 33 21291 4556 110563419
Quality of life decreased 75.54 15.02 42 21282 14127 110553848
Abdominal distension 75.22 15.02 127 21197 174976 110392999
Hospice care 72.09 15.02 39 21285 12434 110555541
Confusional state 69.21 15.02 223 21101 468457 110099518
Cirrhosis alcoholic 62.18 15.02 18 21306 1081 110566894
Small intestinal obstruction 60.54 15.02 50 21274 32163 110535812
Nerve injury 60.53 15.02 33 21291 10680 110557295
Incontinence 59.18 15.02 38 21286 16597 110551378
Blood bilirubin increased 58.97 15.02 73 21251 75899 110492076
Mental status changes 54.10 15.02 70 21254 76052 110491923
Oesophageal varices haemorrhage 51.18 15.02 23 21301 4922 110563053
Asterixis 50.45 15.02 20 21304 3138 110564837
Paracentesis 49.59 15.02 16 21308 1384 110566591
Drug specific antibody 49.02 15.02 19 21305 2809 110565166
Abdominal pain 48.83 15.02 212 21112 512777 110055198
Pseudomembranous colitis 48.50 15.02 24 21300 6367 110561608
Hyperammonaemia 47.93 15.02 31 21293 13701 110554274
Diarrhoea 46.30 15.02 376 20948 1139129 109428846
Jaundice 44.50 15.02 56 21268 59180 110508795
Megacolon 44.48 15.02 20 21304 4285 110563690
Multiple organ dysfunction syndrome 43.91 15.02 93 21231 151617 110416358
Arthropathy 43.76 15.02 3 21321 287519 110280456
Portal vein thrombosis 40.59 15.02 22 21302 7036 110560939
Hepatitis C 40.52 15.02 27 21297 12546 110555429
Sopor 40.05 15.02 42 21282 36504 110531471
Peritonitis bacterial 39.80 15.02 25 21299 10508 110557467
Rheumatoid arthritis 38.25 15.02 6 21318 299607 110268368
Maternal exposure during pregnancy 37.81 15.02 3 21321 254880 110313095
Anaemia 34.94 15.02 202 21122 546884 110021091
Musculoskeletal stiffness 34.83 15.02 6 21318 279816 110288159
Hypervolaemia 34.38 15.02 45 21279 49415 110518560
Hepatic infarction 33.89 15.02 11 21313 970 110567005
Nasopharyngitis 33.66 15.02 17 21307 394344 110173631
Ureaplasma infection 32.64 15.02 12 21312 1534 110566441
Joint swelling 32.31 15.02 23 21301 442822 110125153
Glossodynia 31.87 15.02 3 21321 222001 110345974
Sinusitis 31.62 15.02 9 21315 296679 110271296
Wound 31.55 15.02 4 21320 234433 110333542
Hyperammonaemic encephalopathy 31.43 15.02 17 21307 5417 110562558
Pericarditis 31.35 15.02 3 21321 219111 110348864
Drug hypersensitivity 31.32 15.02 25 21299 454065 110113910
Renal failure 30.85 15.02 105 21219 226469 110341506
Lower respiratory tract infection 30.73 15.02 5 21319 243101 110324874
Alopecia 30.71 15.02 16 21308 364737 110203238
Abdominal cavity drainage 30.60 15.02 10 21314 901 110567074
Liver disorder 29.97 15.02 77 21247 142166 110425809
Acute kidney injury 29.77 15.02 217 21107 635213 109932762
Hypoalbuminaemia 29.45 15.02 32 21292 28942 110539033
Hepatic cancer 29.01 15.02 21 21303 11135 110556840
Portal shunt 28.77 15.02 6 21318 89 110567886
Treatment noncompliance 28.77 15.02 51 21273 72939 110495036
Portal shunt procedure 28.65 15.02 5 21319 26 110567949
Drug intolerance 28.51 15.02 22 21302 406490 110161485
Splenomegaly 28.36 15.02 29 21295 24469 110543506
Haematemesis 28.22 15.02 45 21279 59063 110508912
Vascular device infection 27.67 15.02 24 21300 16488 110551487
Rectal haemorrhage 27.48 15.02 67 21257 119766 110448209
Frequent bowel movements 27.01 15.02 49 21275 71341 110496634
Therapeutic product effect decreased 26.80 15.02 7 21317 244309 110323666
Hyperbilirubinaemia 26.29 15.02 31 21293 30640 110537335
Poverty of speech 25.99 15.02 8 21316 593 110567382
Stomatitis 25.64 15.02 10 21314 270232 110297743
Clostridium test positive 24.95 15.02 19 21305 10874 110557101
Condition aggravated 24.78 15.02 233 21091 734603 109833372
Hepatic lesion 24.42 15.02 17 21307 8476 110559499
Gastric antral vascular ectasia 24.20 15.02 9 21315 1188 110566787
Acute hepatic failure 23.54 15.02 32 21292 36436 110531539
Musculoskeletal toxicity 23.39 15.02 6 21318 228 110567747
Gastric varices 23.01 15.02 8 21316 871 110567104
Impaired healing 22.83 15.02 5 21319 196712 110371263
Microscopic enteritis 22.66 15.02 3 21321 0 110567975
Hepatic mass 22.34 15.02 11 21313 2887 110565088
Hepatic hydrothorax 22.25 15.02 5 21319 107 110567868
Pancreatitis 22.20 15.02 53 21271 93480 110474495
Exposure during pregnancy 22.18 15.02 3 21321 167421 110400554
Functional gastrointestinal disorder 21.96 15.02 14 21310 6035 110561940
Rash 21.85 15.02 83 21241 820881 109747094
Ammonia abnormal 21.31 15.02 6 21318 326 110567649
Flatulence 21.28 15.02 37 21287 52112 110515863
Febrile neutropenia 21.13 15.02 18 21306 316749 110251226
Swelling 21.01 15.02 22 21302 351019 110216956
C-reactive protein increased 20.78 15.02 8 21316 217911 110350064
Blister 20.62 15.02 9 21315 227367 110340608
Spider naevus 20.41 15.02 5 21319 157 110567818
Lung disorder 20.05 15.02 5 21319 180042 110387933
Disease complication 19.96 15.02 13 21311 5814 110562161
Model for end stage liver disease score increased 19.89 15.02 4 21320 49 110567926
Therapy cessation 19.85 15.02 33 21291 44824 110523151
Hypertension 19.85 15.02 43 21281 510041 110057934
Injury 19.59 15.02 5 21319 177260 110390715
Alpha 1 foetoprotein increased 19.33 15.02 7 21317 857 110567118
Hepatic enzyme increased 19.33 15.02 20 21304 320872 110247103
Haemorrhagic diathesis 19.22 15.02 14 21310 7494 110560481
Mobility decreased 19.12 15.02 11 21313 237411 110330564
Asthma 18.24 15.02 13 21311 250278 110317697
Cytomegalovirus infection reactivation 18.20 15.02 20 21304 18313 110549662
Product distribution issue 18.16 15.02 11 21313 4335 110563640
Neuropathy peripheral 18.08 15.02 6 21318 179271 110388704
Sprue-like enteropathy 17.91 15.02 8 21316 1688 110566287
Overgrowth bacterial 17.86 15.02 5 21319 266 110567709
Clostridium difficile colitis 17.78 15.02 31 21293 43747 110524228
Non-alcoholic steatohepatitis 17.74 15.02 9 21315 2518 110565457
Pain 17.59 15.02 110 21214 954845 109613130
Psoriatic arthropathy 17.51 15.02 8 21316 196753 110371222
Rhabdomyolysis 17.44 15.02 57 21267 120344 110447631
Hypoproteinaemia 17.33 15.02 12 21312 5933 110562042
Biopsy liver 17.31 15.02 6 21318 647 110567328
Abdominal discomfort 17.22 15.02 31 21293 393827 110174148
Therapeutic product effect incomplete 17.14 15.02 11 21313 223794 110344181
Completed suicide 17.13 15.02 13 21311 242368 110325607
Osteoarthritis 16.92 15.02 7 21317 182616 110385359
Product use complaint 16.86 15.02 10 21314 3793 110564182
Hypoglycaemia 16.85 15.02 55 21269 116049 110451926
Hypersensitivity 16.60 15.02 33 21291 403965 110164010
Hepatic infection 16.56 15.02 7 21317 1292 110566683
Enterococcus test positive 16.56 15.02 9 21315 2895 110565080
Disease recurrence 16.13 15.02 36 21288 60748 110507227
Factor V inhibition 15.92 15.02 5 21319 396 110567579
Discomfort 15.84 15.02 11 21313 214696 110353279
Dehydration 15.76 15.02 100 21224 279411 110288564
External ear neoplasm malignant 15.66 15.02 3 21321 28 110567947
Pneumatosis intestinalis 15.53 15.02 13 21311 8516 110559459
Ornithine transcarbamoylase deficiency 15.21 15.02 3 21321 33 110567942
Fibromyalgia 15.13 15.02 7 21317 170902 110397073

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07AA11 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
ATC D06AX11 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
ANTIBIOTICS FOR TOPICAL USE
Other antibiotics for topical use
FDA CS M0019113 Rifamycins
FDA EPC N0000175500 Rifamycin Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D005765 Gastrointestinal Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:53784 antispasmodic drug
CHEBI has role CHEBI:55324 gastrointestinal drug
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:71031 orphan drug
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

A07AA Antibiotics 12 drugs
amphotericin BcolistinfidaxomicinkanamycinnatamycinneomycinnystatinparomomycinPolymyxin Brifamycinstreptomycinvancomycin
D06AX Other antibiotics for topical use 12 drugs
amikacinbacitracinchloramphenicolfusidic acidgentamicinmupirocinneomycinozenoxacinretapamulinrifamycintyrothricinvirginiamycin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hepatic encephalopathy indication 13920009 DOID:13413
Irritable bowel syndrome with diarrhea indication 197125005
Diarrhea due to E. Coli indication
Traveler's diarrhea off-label use 11840006
Hemorrhagic diarrhea contraindication 95545007
Fever contraindication 386661006
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.02 acidic
pKa2 7.28 acidic
pKa3 11.32 acidic
pKa4 12.55 acidic
pKa5 2.08 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG XIFAXAN SALIX PHARMS N021361 May 25, 2004 RX TABLET ORAL 10703763 Feb. 27, 2026 TREATMENT OF TRAVELERS DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
200MG XIFAXAN SALIX PHARMS N021361 May 25, 2004 RX TABLET ORAL 8741904 Feb. 27, 2026 TREATMENT OF TRAVELERS DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10703763 Feb. 27, 2026 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10703763 Feb. 27, 2026 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8741904 Feb. 27, 2026 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8741904 Feb. 27, 2026 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8741904 Feb. 27, 2026 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8193196 Sept. 2, 2027 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8193196 Sept. 2, 2027 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10456384 Feb. 26, 2029 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10456384 Feb. 26, 2029 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10765667 Feb. 26, 2029 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10765667 Feb. 26, 2029 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 11564912 Feb. 26, 2029 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 11564912 Feb. 26, 2029 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS AND SYMPTOMS THEREOF
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 11779571 Feb. 26, 2029 TREATMENT OF BLOATING ASSOCIATED WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D) IN ADULT FEMALE SUBJECTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8309569 July 18, 2029 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8309569 July 18, 2029 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF
200MG XIFAXAN SALIX PHARMS N021361 May 25, 2004 RX TABLET ORAL 7928115 July 24, 2029 METHOD OF TREATING TRAVELERS DIARRHEA
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10314828 July 24, 2029 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10335397 July 24, 2029 REDUCTION IN A SUBJECTS RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 10709694 July 24, 2029 REDUCTION IN A SUBJECTS RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8829017 July 24, 2029 TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8946252 July 24, 2029 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 9421195 July 24, 2029 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 9629828 July 24, 2029 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8642573 Oct. 2, 2029 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
550MG XIFAXAN SALIX PHARMS N021361 March 24, 2010 RX TABLET ORAL 8969398 Oct. 2, 2029 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor EC50 5.66 CHEMBL
Bacterial DNA-directed RNA polymerase Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4021474 VUID
N0000148858 NUI
D02554 KEGG_DRUG
4021474 VANDF
C0073374 UMLSCUI
CHEBI:75246 CHEBI
RXM PDB_CHEM_ID
CHEMBL1617 ChEMBL_ID
D000078262 MESH_DESCRIPTOR_UI
DB01220 DRUGBANK_ID
12012 IUPHAR_LIGAND_ID
5244 INN_ID
L36O5T016N UNII
6436173 PUBCHEM_CID
35619 RXNORM
18641 MMSL
54029 MMSL
d05294 MMSL
007765 NDDF
412553001 SNOMEDCT_US
412554007 SNOMEDCT_US
L36O5T016N INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 50090-2445 TABLET 200 mg ORAL NDA 24 sections
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 54868-5972 TABLET 200 mg ORAL NDA 26 sections
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 54868-6154 TABLET 550 mg ORAL NDA 26 sections
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 55154-6777 TABLET 550 mg ORAL NDA 24 sections
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 65649-301 TABLET 200 mg ORAL NDA 24 sections
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 65649-303 TABLET 550 mg ORAL NDA 24 sections
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 68151-4980 TABLET 200 mg ORAL NDA 26 sections
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 68258-1107 TABLET 200 mg ORAL NDA 26 sections
XIFAXAN HUMAN PRESCRIPTION DRUG LABEL 1 69189-0309 TABLET 200 mg ORAL NDA 26 sections